Hypothesis

Rapamycin‑mediated lifespan extension depends on enhanced removal of circulating cell‑free DNA (cfDNA) from the bloodstream, rather than on reversal of age‑related nucleosome disruptions or methylation changes. If cfDNA clearance is blocked, rapamycin will fail to extend lifespan despite sustained mTORC1 inhibition and stress‑response activation.

Rationale

• mTORC1 inhibition by rapamycin boosts autophagy in hepatocytes and sinusoidal endothelial cells, increasing their capacity to phagocytose nucleic‑acid debris [1].
• Aged plasma shows elevated cfDNA levels, a shift toward shorter fragments, and altered methylation patterns that reflect ongoing cell turnover and nucleosome instability [3]. These signatures persist under rapamycin treatment, indicating that molecular damage is not repaired.
• Persistent cfDNA can activate TLR9 in immune cells, driving inflamm‑aging [3]. Faster cfDNA clearance would lower TLR9 signaling, reducing chronic inflammation without fixing the underlying nucleosome defects.

Thus, the longevity benefit may stem from a detoxification effect—clearing harmful nucleic‑acid debris—while the cell continues to operate under a simulated scarcity state.

Testable Predictions

1. cfDNA kinetics – In rapamycin‑treated mice, plasma cfDNA concentration will decline faster after an acute endothelial injury (e.g., laser‑induced microvascular damage) compared with controls, reflecting increased clearance.
2. Clearance dependency – Depleting liver sinusoidal endothelial cells (LSECs) or inhibiting their phagocytic receptors (e.g., using fucoidan to block SR‑A or mannose receptors) will blunt the cfDNA clearance acceleration and abolish rapamycin‑induced lifespan extension, even though mTORC1 remains inhibited (verified by p‑S6K levels).
3. Inflammation read‑out – LSEC depletion will restore elevated plasma IL‑6 and TNF‑α levels in rapamycin‑treated mice, linking cfDNA persistence to inflamm‑aging.
4. Methylation unchanged – Genome‑wide cfDNA methylation arrays will show no significant shift toward youthful patterns in any condition, confirming that rapamycin does not repair epigenetic damage.

Experimental Design (Outline)

• Groups (n = 15 per group, male C57BL/6J, 20 mo old):
  1. Vehicle control
  2. Rapamycin (14 ppm diet)
  3. Rapamycin + clodronate liposomes (LSEC depletion)
  4. Rapamycin + fucoidan (phagocytosis blockade)
  5. Clodronate liposomes alone (control for depletion effects)
• Measurements (baseline, 4 wk, 12 wk):
  • Plasma cfDNA concentration and fragment size (qPCR, Bioanalyzer)
  • cfDNA methylation at 2000 age‑related CpGs (EPIC array)
  • Hepatic autophagy markers (LC3‑II, p62)
  • LSEC phagocytic activity (ex vivo uptake of fluorescent DNA)
  • Serum cytokines (IL‑6, TNF‑α, IFN‑β)
  • Survival curves

Potential Outcomes & Interpretation

• If rapamycin accelerates cfDNA clearance and this effect is lost with LSEC depletion/fucoidan, while lifespan extension parallels the clearance phenotype, the hypothesis is supported.
• If lifespan extension persists despite blocked cfDNA clearance, then rapamycin must act through another mechanism (e.g., direct metabolic reprogramming), falsifying the hypothesis.
• Persistent youthful cfDNA methylation patterns under any condition would indicate that rapamycin does repair epigenetic damage, also contradicting the core claim.

This framework links nutrient‑sensing pathways to the biophysical fate of nucleic‑acid waste, offering a concrete, falsifiable test of whether mTOR inhibition impersonates a harder life by merely cleaning up its molecular debris.